Lataa...
Metformin and cancer: Quo vadis et cui bono?
How many lives have already been saved by the anti-cancer drug metformin? Inadvertently perhaps, among the millions of type 2 diabetics with occult or known cancers and who have been prescribed metformin since the 1950s, thousands may have benefited from the anticancer properties of this first-line...
Tallennettuna:
| Julkaisussa: | Oncotarget |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Impact Journals LLC
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5342329/ https://ncbi.nlm.nih.gov/pubmed/27356748 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10262 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|